No Wrinkles in Actavis' $66 Billion Deal to Buy Botox Maker Allergan

SUGAR LAND--December 3, 2014--Reported by Annette Kreuger for Industrial Info Resources (Sugar Land, Texas)--Pharmaceutical company Allergan (NYSE:AGN) (Irvine, California) has accepted a $66 billion buyout offer from Actavis (NYSE:ACT) (Dublin, Ireland), following months of pursuit by Valeant Pharmaceuticals (NYSE:VRX) (Laval, Quebec). Allergan, known chiefly for wrinkle reducer Botox, had continually spurned Valeant's offers, which had reached a peak of $53 billion last May.

Within this article: Details on the buyout, including a list of plants tracked by Industrial Info.